WO1996022114A1 - An antimicrobial medical device and method - Google Patents
An antimicrobial medical device and method Download PDFInfo
- Publication number
- WO1996022114A1 WO1996022114A1 PCT/US1996/000842 US9600842W WO9622114A1 WO 1996022114 A1 WO1996022114 A1 WO 1996022114A1 US 9600842 W US9600842 W US 9600842W WO 9622114 A1 WO9622114 A1 WO 9622114A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- triclosan
- medical device
- polymeric material
- polyurethane
- tubing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/04—Macromolecular materials
- A61L29/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/16—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/06—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/202—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with halogen atoms, e.g. triclosan, povidone-iodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
- A61L2300/206—Biguanides, e.g. chlorohexidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/602—Type of release, e.g. controlled, sustained, slow
Definitions
- the present invention relates generally to a medical device, and more particularly to an antimicrobial medical device made from a polymeric material with an antimicrobial drug incorporated within the polymeric matrix, as well as a method for making such a device.
- CVCs central venous catheters
- percutaneous catheters disrupt the body's primary barrier to infection, which is the intact skin surface.
- the wound tract created by catheter placement provides a direct route for the invasion of microorganisms that cause infections. These infections are typically caused by microorganisms colonizing the surface of the skin.
- CNS Coagulase-negative staphylococci
- CNS reside as predominant members of the normal skin flora and possess the ability to adhere to and colonize indwelling medical devices.
- CNS are spherical, gram-positive organisms which cause a variety of diseases in man. Because CNS frequently become drug-resistant, they have risen to a position of special significance in clinical medicine.
- CNS are uniquely adaptive in exploiting the microenvironment of a percutaneous foreign body. Once established, removal of the device is often necessary to resolve the infection caused by these organisms.
- CVCs are percutaneously placed acute catheters that have an estimated duration of about one week.
- the most frequent life-threatening complication from the use of CVCs is septicemia. Even though the use is relatively short term, a CVC- related sepsis rate of 4% is typical. Such infections can prolong hospitalization by an average of 7 days. Unfortunately, CVC-sepsis also has a 10- 20% fatality rate.
- the mean duration is approximately 3 to 4 months.
- infection is a constant threat because the presence of a foreign body will, for a variety of reasons, compromise the normal immune mechanisms of the host against infection.
- an infection may result in the discontinuation of therapy, rehospitalization and possibly additional surgery to remove the implant, not to mention the costs and risks associated therewith. Therefore, prevention of such infections is preferable to treatment, especially when associated with medical devices that are instrumental for patient care.
- Many different approaches have been tried to reduce catheter related infection problems. Since these infections are most often associated with bacteria colonizing the catheter surface and forming a biofilm, many schemes have focused on preventing this from occurring.
- a second approach involves the use of antimicrobial agent delivered from the polymer. This can be done with a compound that diffuses from the device surface.
- Different techniques are available to make a catheter into a controlled drug delivery device.
- the use of a coating containing the drug of interest is well known.
- the advantage of a coating is that it can be applied to a finished device to add the desired antimicrobial feature.
- the drug 2,4,4 '-trichloro-2 •-hydroxy diphenyl ether commonly known as triclosan, is a synthetic antimicrobial agent that is commonly used as an adjunct in cosmetics, soaps and dermatological formulations. It also has limited water solubility, about 10-20 ppm.
- Triclosan has a broad antimicrobial spectrum at low concentration and, is active against both gram-positive and gram-negative bacteria, yeast and other fungi. Also, this agent demonstrates a low toxicity and superior activity against CNS.
- an antimicrobial agent in the polymeric material used to make medical devices.
- Another object of the present invention is to provide an antimicrobial medical device that releases an antimicrobial agent in a controlled manner to provide biocidal properties that are safe and long lasting.
- the present invention is directed to a medical device made of a polymeric material that combines polyurethane and an antimicrobial agent, or combination of agents, that acts as a plasticizer in the formation of the polymeric material.
- the antimicrobial agent is held in the polymeric matrices, so that migration is inhibited, causing the controlled release of the agent.
- the present invention also provides a method of making the antimicrobial medical device wherein an antimicrobial agent is incorporated into the device by blending the agent into the polymer resin before or during extrusion.
- the preferred antimicrobial agent is triclosan, which is particularly effective against staphylococci. Combinations of triclosan with biguanides or silver compounds can also be used in the present device. In polyurethane, triclosan will provide long lasting protection against colonization by a broad spectrum of microbes.
- Triclosan has unexpected physical properties that render it soluble and completely iscible in polyurethane so that it acts as a plasticizer. As a result, the triclosan can have a high loading in the polyurethane without causing a phase separation. Depending on the specific polymer, the triclosan may obviate the need to use a separate plasticizer in the polymeric material. The triclosan will soften the polymer for processing and provide a degree of elasticity in the formed device. Triclosan is effective at killing certain skin flora, which is the source of infection for most percutaneous and indwelling medical devices.
- the biguanides that may be used in the present invention in combination with the triclosan include chlorhexidine acetate, chlorhexidine gluconate, chlorhexidine hydrochloride and chlorhexidine sulfate, as well as other salts of chlorhexidine.
- the silver compounds that may be used in the present invention in combination with the triclosan include silver acetate, silver benzoate, silver carbonate, silver iodate, silver iodide, silver lactate, silver laurate, silver nitrate, silver oxide, silver palmitate, silver protein, and silver sulfadiazine.
- the medical devices made according to the present invention include catheters, stents, shunts, drainage tubes and other percutaneous devices.
- the term "safe and effective amount” means an amount of antimicrobial agent and/or mixture thereof which is capable of retarding or preventing microbial colonization and adherence to the surface of the polymeric materials used herein while causing minimum undesirable side effects when in contact with living tissue.
- the amount delivered is above the minimum inhibitory concentration of the targeted microorganisms.
- Figure 1 is a graph of the serial zone transfer data for extruded blended tubing of the present invention and 5% swell loaded tubing.
- Figure 2 is a graph of the serial zone transfer data for the explanted samples tubing used in the in-vivo studies.
- Figure 3 is a graph of the assay data for the explanted tubing samples used in the in-vivo studies.
- the simplest method of incorporating the antimicrobial agent, triclosan is by direct compounding of the drug into the urethane resin before extrusion. It is a low cost process and the resulting drug reservoir is large. This can be done only because the drug is compatible with the polymeric material.
- polyurethane is easily shaped into three-dimensional structures. Once molded, the formed antimicrobial products are dimensionally stable even after repeated exposure to boiling water and moderately high temperatures.
- polyurethane means a thermoplastic polymer produced by the condensation reaction of a polyisocyanate and a hydroxyl-containing material, including ether-based polyurethane, ester-based polyurethane, poly(ether urethane urea) , silicone urethane, in particular, aliphatic or aromatic diisocyanates used in various combinations with polyether, aliphatic or aromatic polyester soft segments to make the thermoplastic polyurethane.
- Soft segments include high molecular weight polyols with glass transition temperatures typically below room temperature.
- the preferred polyurethanes have soft segment compositions that are polyether-based or are highly aliphatic. Less preferred polyurethanes are those with polyester soft segments.
- the polyurethane must be biocompatible, elastomeric and processable, as well as be able to solubilize triclosan.
- the polymeric material acts as a reservoir for the triclosan and uniform distribution acts to optimize the loading.
- triclosan can be incorporated in amounts up to 30% by weight in Tecoflex 80A with no phase separation problems.
- Tecoflex is a registered trademark of Thermedics, Inc.
- Tecoflex 80A is an 80 Shore A durometer thermoplastic polyether urethane manufactured using an aliphatic diisocyanate and polyether soft segment. In the polyurethanes of the present invention, the triclosan acts as a plasticizer.
- plasticizers are used in processing polymer materials to soften and improve flow during extrusion without causing any significant loss in other physical properties, such as stiffness, elongation set, etc.
- Plasticizer can also be used to lower the durometer of a polymeric device.
- the typical plasticizer will leach out slowly and can be toxic. The present use of triclosan alleviates this concern.
- the preferred loading of triclosan is in the range of 0.5 to 15.0 percent by weight.
- the more preferred loading of triclosan is in the range of 1.0 to 10.0 percent by weight.
- the most preferred loading of triclosan is in the range of 5.0 to 10.0 percent.
- the ultimate loading to attain the required physical properties is dependent, in part, on the durometer of the polymer used.
- the loading of the triclosan in the present invention can be obtained for durometer values from 75 Shore A to 60 Shore D. For a given softness of the drug loaded polymer, the triclosan loading is higher for polyurethanes of greater durometer.
- Extrusion requires that the antimicrobial agent have good thermal stability, which is satisfied by triclosan since it exhibits no significant decomposition below 280-290 ⁇ C. Triclosan has a measurable vapor pressure at higher temperatures. According to the method of the present invention, extrusion of Tecoflex EG-80A resin is typically carried out at about 160-175°C.
- the drug delivery characteristics of triclosan from polyurethane are well suited for antimicrobial devices.
- Triclosan is very soluble in urethane and can diffuse through the polymeric material.
- the triclosan is incorporated into the polymeric matrix and is released when the device is used.
- the concentration of drug immediately adjacent to the device depends on the initial concentration of the triclosan, the partition coefficient between the polymer and water, the diffusivity of the triclosan in the urethane, and the rate the drug is swept away from the device.
- the partition coefficient can be set forth by the following equation: wt.% drug in water polySSiST co ⁇ " lclent ⁇ vt.% drug in As shown by the present invention, 5% triclosan loading in 80A polyurethane has a partition coefficient of less than lxlO "4 .
- the drug delivery rate is also limited by the very low solubility of triclosan in water and its very low partition coefficient between water and polyurethane. These factors prevent the drug from reaching a saturated concentration that is, for example, cytotoxic to red blood cells. In measurements taken in a phosphate buffered saline solution, triclosan has saturation concentration of 16 ppm, which is safe and not toxic to red blood cells.
- the delivery rate is such that the concentration of the drug at the polymer surface is above the minimum inhibitory concentration (MIC) of the targeted microbes so as to be effective.
- the medical devices of the present invention have the resulting advantageous property of a long duration of activity.
- the resin pellets can be "tumble coated" with triclosan; the resin pellets can be compounded with triclosan using a twin screw compounder; the starting ingredients can be pelletized together using a twin screw machine; and the resin pellets can be compounded with the triclosan using an extruder/compounder machine.
- Compounding the triclosan and extruding in a single process step is preferred, because the resulting material will have a higher durometer.
- the resin pellets, triclosan and other ingredients can also be fed into the compounder at a suitable rate.
- the ingredients are melted, blended and then extruded into strands.
- the strands may be pelletized and dried prior to further processing.
- the homogeneous pellets of polymer and triclosan, prepared as described above, may be remelted and molded or extruded into the desired shape of the medical device.
- Tecoflex Blue (293) single lumen 0.110 x. 0.065 0% triclosan EG- 5A-B20 (control)
- the resins used were 20% by weight of barium sulphate for radiopacity.
- the triclosan was blended directly into the Tecoflex resin, which was repelletized by a water pelletizer and extruded to form the tubing.
- the extrusion was performed without any difficulties.
- the plasticizer effect of the triclosan permitted the extrusion to be performed at lower temperatures, which may offer a manufacturing advantage.
- the physical characteristics of tubing made by the present invention were compared with the control tubing made with triclosan and similar commercially available tubing. For example, the surface of the extruded tubing of the present invention was inspected under an optical microscope. It was found that both the exterior and intraluminal surfaces of the tubing of the present invention were smoother than the control samples and commercially available samples of 9 Fr.
- tubing from Strato Medical. At room temperature, the drug loaded formulations were not sticky and exhibited no blocking behavior. At 40 C C, the 80A tubing with drug was softer but did not block. At 60°C, the 85A tubing blocked slightly, but the lumen would spring back open. However, at 60°C, the 80A tubing tended to stay closed when squeezed.
- Figure 1 contains the data from the serial zone transfer tests, which are plotted as size of the zone versus time. It was discovered that the 85A tubing and the 5% swell loaded tubing had the same zone behavior during the 5 day test period. Zone size is only moderately sensitive to the drug delivery rate.
- Triclosan that was swell loaded into polyurethane tubing was used for feasibility in-vivo studies, as described below.
- the zone tests conducted on swell loaded polyurethane tubing showed results that were similar to using the blended ingredients.
- swell loading is a simple technique which involves soaking the polyurethane article in a solution containing the triclosan, drying it, and then performing a quick rinse. Swell loading, however, yields a non-uniform drug distribution.
- a major drawback of swell loading is that some polymer is extracted and other additives, such as extrusion lubricants and stabilizers, can be leached out as well.
- the direct blending of the triclosan in the present invention does not have these disadvantages.
- tube samples with nominal values of "5%” and “10%” of triclosan were prepared by swell loading.
- the 5% swell loaded tubing contained in the range of 5.5 to 6.1% triclosan, by weight, and the 10% swell loaded tubing contained about 13.9% triclosan, by weight.
- the swell loaded tubing was cut into 2 cm segments and sterilized. The lumen of the tube sections were left open. Control sets of tubing with no drug were also prepared.
- the tube samples were implanted intramuscularly in the backs of white New Zealand rabbits. For each point in time when explants were to be taken, samples of six tube segments for each type of loaded tubing and two control tubing were prepared and implanted. Explants were taken at 30, 60 and 90 days. Upon retrieval, the implant sites were examined acroscopically and all samples were scored as benign. Further histopathology tests on the implant sites confirmed these initial observations. While rabbit implant studies were not designed to measure long term biostability of materials, nevertheless, the samples tested showed only minor differences between the drug and non-drug loaded samples.
- Zone of inhibition assays were performed using the recovered explanted samples as well.
- Figure 2 shows the data plotted as zone size versus time.
- the test organism was Staph. epidermidis in two different types of agar, i.e., MH and blood agars. After 90 days, both the 10% and 5% samples were still active. As clearly shown in Figure 2 # the 10% drug samples give bigger zones than the 5% samples.
- the results showed that the delivery of the triclosan was not controlled only by the aqueous solubility, since the 10% and 5% samples did not have the same size zones, but may also be controlled by the diffusion rate in the polymeric material. Distribution of the triclosan in the polymeric material will also be a factor in the delivery rate.
- the triclosan content of the explanted samples were assayed by dissolving the polymer in solvent and measuring the triclosan concentration by UV-vis spectrophotometry.
- the drug concentrations from the explanted samples are listed in Table 3 below.
- plotting the above data shows an exponential decay.
- the above tests show that the extruded blended tubing can be expected to perform as intended and to be effective over an extended period of time.
- Triclosan present in an amount of about 5%, by weight, will be effective for about 45 days against a microorganism with an MIC of about 1 ppm.
- the medical devices made from polyurethanes and triclosan in the present invention will provide long lasting protection against infection.
- the triclosan will be delivered in an amount that is above the minimum inhibitory concentration of the targeted microorganisms, including CNS, to prevent colonization of the device surface.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP8522425A JPH11500330A (en) | 1995-01-18 | 1996-01-18 | Antimicrobial medical device and method |
AU47636/96A AU4763696A (en) | 1995-01-18 | 1996-01-18 | An antimicrobial medical device and method |
EP96903614A EP0804256A1 (en) | 1995-01-18 | 1996-01-18 | An antimicrobial medical device and method |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37429095A | 1995-01-18 | 1995-01-18 | |
US08/374,290 | 1995-01-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1996022114A1 true WO1996022114A1 (en) | 1996-07-25 |
WO1996022114A9 WO1996022114A9 (en) | 1996-10-03 |
Family
ID=23476119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/000842 WO1996022114A1 (en) | 1995-01-18 | 1996-01-18 | An antimicrobial medical device and method |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0804256A1 (en) |
JP (1) | JPH11500330A (en) |
AU (1) | AU4763696A (en) |
CA (1) | CA2210119A1 (en) |
WO (1) | WO1996022114A1 (en) |
Cited By (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997014447A1 (en) * | 1995-10-13 | 1997-04-24 | Paul Kenneth Priscott | Biomaterials for use in medical applications |
EP0874655A1 (en) * | 1996-01-05 | 1998-11-04 | E.I. Du Pont De Nemours And Company | Triclosan-containing medical devices |
WO1999048542A1 (en) * | 1998-03-20 | 1999-09-30 | Bayer Aktiengesellschaft | Moulded bodies made of thermoplastic polyurethane containing an active substance |
AU712132B2 (en) * | 1995-10-13 | 1999-10-28 | Paul Kenneth Priscott | Improvements in implantable medical devices |
WO1999060297A1 (en) * | 1998-05-18 | 1999-11-25 | Valpar Industrial Limited | Antimicrobial plastic tubing |
WO2000028815A1 (en) * | 1998-11-12 | 2000-05-25 | Bayer Aktiengesellschaft | Aromatic copolyester containing active ingredients |
WO2000028814A1 (en) * | 1998-11-12 | 2000-05-25 | Bayer Aktiengesellschaft | Polyether block amides containing active substances |
WO2000044414A1 (en) * | 1999-01-28 | 2000-08-03 | Union Carbide Chemicals & Plastics Technology Corporation | Lubricious medical devices |
WO2000057933A1 (en) * | 1999-03-31 | 2000-10-05 | The Trustees Of Columbia University In The City Of New York | Triclosan and silver compound containing medical devices |
EP1102532A1 (en) * | 1998-07-29 | 2001-05-30 | Microban Products Company | Antimicrobial treatment of enclosed systems having continuous or intermittent fluid flow |
EP1190622A1 (en) * | 2000-09-21 | 2002-03-27 | Ciba SC Holding AG | Mixtures of phenolic and inorganic materials with antimicrobial activity |
WO2005051448A1 (en) * | 2003-11-26 | 2005-06-09 | Ethicon Gmbh | Surgical implants for controlled release of medicaments |
WO2006000413A1 (en) * | 2004-06-23 | 2006-01-05 | Hansgrohe Ag | Sanitary hose produced from flexible plastic having an antibacterial finish |
US7537779B2 (en) | 2000-12-22 | 2009-05-26 | The Trustees Of Columbia University In The City Of New York | Antimicrobial medical devices |
US7901705B2 (en) | 2006-02-28 | 2011-03-08 | Tyco Healthcare Group Lp | Antimicrobial releasing polymers |
DE202004021828U1 (en) | 2004-03-09 | 2011-06-01 | Aesculap AG, 78532 | Antimicrobial medical product |
US7993390B2 (en) | 2002-02-08 | 2011-08-09 | Boston Scientific Scimed, Inc. | Implantable or insertable medical device resistant to microbial growth and biofilm formation |
EP2359875A2 (en) | 2005-09-15 | 2011-08-24 | Aesculap AG | Biocompatible antimicrobial filament material |
US8105520B2 (en) | 2002-02-08 | 2012-01-31 | Boston Scientific Scimed, Inc, | Implantable or insertable medical device resistant to microbial growth and biofilm formation |
US8147857B2 (en) | 2004-12-21 | 2012-04-03 | Bayer Innovation Gmbh | Infection-resistant polyurethane foams, method for producing the same and use thereof in antiseptic wound dressings |
WO2014172569A3 (en) * | 2013-04-18 | 2015-01-29 | Board Of Regents, The University Of Texas System | Antimicrobial catheters |
US9981069B2 (en) | 2007-06-20 | 2018-05-29 | The Trustees Of Columbia University In The City Of New York | Bio-film resistant surfaces |
US11707272B2 (en) | 2012-04-06 | 2023-07-25 | Cilag Gmbh International | Packaged antimicrobial medical device having improved shelf life and method of preparing same |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7513093B2 (en) | 2002-10-04 | 2009-04-07 | Ethicon, Inc. | Method of preparing a packaged antimicrobial medical device |
US9597067B2 (en) | 2002-10-04 | 2017-03-21 | Ethicon, Inc. | Packaged antimicrobial medical device and method of preparing same |
US9474524B2 (en) | 2002-10-04 | 2016-10-25 | Ethicon, Inc. | Packaged antimicrobial medical device having improved shelf life and method of preparing same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5091442A (en) * | 1988-09-07 | 1992-02-25 | Smith And Nephew Plc | Tubular articles |
-
1996
- 1996-01-18 WO PCT/US1996/000842 patent/WO1996022114A1/en not_active Application Discontinuation
- 1996-01-18 EP EP96903614A patent/EP0804256A1/en not_active Withdrawn
- 1996-01-18 AU AU47636/96A patent/AU4763696A/en not_active Abandoned
- 1996-01-18 JP JP8522425A patent/JPH11500330A/en active Pending
- 1996-01-18 CA CA 2210119 patent/CA2210119A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5091442A (en) * | 1988-09-07 | 1992-02-25 | Smith And Nephew Plc | Tubular articles |
Cited By (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6706024B2 (en) | 1995-06-07 | 2004-03-16 | The Trustees Of Columbia University In The City Of New York | Triclosan-containing medical devices |
AU712132B2 (en) * | 1995-10-13 | 1999-10-28 | Paul Kenneth Priscott | Improvements in implantable medical devices |
WO1997014447A1 (en) * | 1995-10-13 | 1997-04-24 | Paul Kenneth Priscott | Biomaterials for use in medical applications |
EP1273313A2 (en) * | 1996-01-05 | 2003-01-08 | The Trustees of Columbia University in the City of New York | Triclosan containing medical devices |
EP1273313A3 (en) * | 1996-01-05 | 2003-02-05 | The Trustees of Columbia University in the City of New York | Triclosan containing medical devices |
EP0874655A1 (en) * | 1996-01-05 | 1998-11-04 | E.I. Du Pont De Nemours And Company | Triclosan-containing medical devices |
US6872195B2 (en) | 1996-01-05 | 2005-03-29 | The Trustees Of Columbia University In The City Of New York | Chlorhexidine-containing medical devices |
EP0874655A4 (en) * | 1996-01-05 | 2001-05-02 | Univ Columbia | Triclosan-containing medical devices |
US6626873B1 (en) | 1996-01-05 | 2003-09-30 | Trustees Of Columbia University | Tricolosan-containing medical devices |
AU737881B2 (en) * | 1998-03-20 | 2001-09-06 | Bayer Aktiengesellschaft | Moulded items made from active substance-containing thermoplastic polyurethanes |
US6723333B1 (en) | 1998-03-20 | 2004-04-20 | Bayer Aktiengesellschaft | Moulded bodies made of thermoplastic polyurethane containing an active substance |
JP2002507457A (en) * | 1998-03-20 | 2002-03-12 | バイエル・アクチエンゲゼルシヤフト | Molded articles made from thermoplastic polyurethanes containing active substances |
WO1999048542A1 (en) * | 1998-03-20 | 1999-09-30 | Bayer Aktiengesellschaft | Moulded bodies made of thermoplastic polyurethane containing an active substance |
WO1999060297A1 (en) * | 1998-05-18 | 1999-11-25 | Valpar Industrial Limited | Antimicrobial plastic tubing |
EP1102532A4 (en) * | 1998-07-29 | 2006-02-08 | Microban Products | Antimicrobial treatment of enclosed systems having continuous or intermittent fluid flow |
EP1102532A1 (en) * | 1998-07-29 | 2001-05-30 | Microban Products Company | Antimicrobial treatment of enclosed systems having continuous or intermittent fluid flow |
WO2000028815A1 (en) * | 1998-11-12 | 2000-05-25 | Bayer Aktiengesellschaft | Aromatic copolyester containing active ingredients |
WO2000028814A1 (en) * | 1998-11-12 | 2000-05-25 | Bayer Aktiengesellschaft | Polyether block amides containing active substances |
US6605069B1 (en) * | 1998-11-12 | 2003-08-12 | Bayer Aktiengesellschaft | Aromatic copolyester containing active ingredients |
US6455059B1 (en) | 1998-11-12 | 2002-09-24 | Bayer Aktiengesellschaft | Polyether block amides containing active substances |
AU745052B2 (en) * | 1998-11-12 | 2002-03-07 | Bayer Aktiengesellschaft | Aromatic copolyester containing active ingredients |
WO2000044414A1 (en) * | 1999-01-28 | 2000-08-03 | Union Carbide Chemicals & Plastics Technology Corporation | Lubricious medical devices |
WO2000057933A1 (en) * | 1999-03-31 | 2000-10-05 | The Trustees Of Columbia University In The City Of New York | Triclosan and silver compound containing medical devices |
US7947297B2 (en) | 2000-09-21 | 2011-05-24 | Basf Se | Mixtures of phenolic and inorganic materials with antimicrobial activity |
EP1190622A1 (en) * | 2000-09-21 | 2002-03-27 | Ciba SC Holding AG | Mixtures of phenolic and inorganic materials with antimicrobial activity |
US7947296B2 (en) | 2000-09-21 | 2011-05-24 | Basf Se | Mixtures of phenolic and inorganic materials with antimicrobial activity |
US6585989B2 (en) | 2000-09-21 | 2003-07-01 | Ciba Specialty Chemicals Corporation | Mixtures of phenolic and inorganic materials with antimicrobial activity |
US7537779B2 (en) | 2000-12-22 | 2009-05-26 | The Trustees Of Columbia University In The City Of New York | Antimicrobial medical devices |
US8906401B2 (en) | 2000-12-22 | 2014-12-09 | The Trustees Of Columbia University In The City Of New York | Antimicrobial medical devices containing chlorhexidine free base and salt |
US9034346B2 (en) | 2002-02-08 | 2015-05-19 | Boston Scientific Scimed, Inc. | Implantable or insertable medical device resistant to microbial growth and biofilm formation |
US8105520B2 (en) | 2002-02-08 | 2012-01-31 | Boston Scientific Scimed, Inc, | Implantable or insertable medical device resistant to microbial growth and biofilm formation |
US7993390B2 (en) | 2002-02-08 | 2011-08-09 | Boston Scientific Scimed, Inc. | Implantable or insertable medical device resistant to microbial growth and biofilm formation |
US8481138B2 (en) | 2002-02-08 | 2013-07-09 | Boston Scientific Scimed, Inc. | Implantable or insertable medical device resistant to microbial growth and biofilm formation |
WO2005051448A1 (en) * | 2003-11-26 | 2005-06-09 | Ethicon Gmbh | Surgical implants for controlled release of medicaments |
DE10355189B4 (en) * | 2003-11-26 | 2015-04-30 | Johnson & Johnson Medical Gmbh | Method for producing a surgical implant and surgical implant |
DE202004021828U1 (en) | 2004-03-09 | 2011-06-01 | Aesculap AG, 78532 | Antimicrobial medical product |
WO2006000413A1 (en) * | 2004-06-23 | 2006-01-05 | Hansgrohe Ag | Sanitary hose produced from flexible plastic having an antibacterial finish |
US8147857B2 (en) | 2004-12-21 | 2012-04-03 | Bayer Innovation Gmbh | Infection-resistant polyurethane foams, method for producing the same and use thereof in antiseptic wound dressings |
EP2359874A2 (en) | 2005-09-15 | 2011-08-24 | Aesculap AG | Biocompatible antimicrobial filament material |
EP2359875A2 (en) | 2005-09-15 | 2011-08-24 | Aesculap AG | Biocompatible antimicrobial filament material |
US7901705B2 (en) | 2006-02-28 | 2011-03-08 | Tyco Healthcare Group Lp | Antimicrobial releasing polymers |
US9981069B2 (en) | 2007-06-20 | 2018-05-29 | The Trustees Of Columbia University In The City Of New York | Bio-film resistant surfaces |
US11707272B2 (en) | 2012-04-06 | 2023-07-25 | Cilag Gmbh International | Packaged antimicrobial medical device having improved shelf life and method of preparing same |
WO2014172569A3 (en) * | 2013-04-18 | 2015-01-29 | Board Of Regents, The University Of Texas System | Antimicrobial catheters |
EP2986342A4 (en) * | 2013-04-18 | 2016-12-14 | Univ Texas | Antimicrobial catheters |
US10744232B2 (en) | 2013-04-18 | 2020-08-18 | Board Of Regents, The University Of Texas System | Antimicrobial catheters |
EP3777977A1 (en) * | 2013-04-18 | 2021-02-17 | Board of Regents, The University of Texas System | Antimicrobial catheters |
US11738119B2 (en) | 2013-04-18 | 2023-08-29 | Board Of Regents, The University Of Texas System | Antimicrobial catheters |
Also Published As
Publication number | Publication date |
---|---|
AU4763696A (en) | 1996-08-07 |
CA2210119A1 (en) | 1996-07-25 |
JPH11500330A (en) | 1999-01-12 |
EP0804256A1 (en) | 1997-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1996022114A1 (en) | An antimicrobial medical device and method | |
WO1996022114A9 (en) | An antimicrobial medical device and method | |
EP0379271B1 (en) | Anti-infective and lubricious medical articles and method for their preparation | |
EP0379269B1 (en) | Anti-infection and antithrombogenic medical articles and method for their preparation | |
US6261271B1 (en) | Anti-infective and antithrombogenic medical articles and method for their preparation | |
US5707366A (en) | Anti-infective and antithrombogenic medical articles and method for their preparation | |
US5013306A (en) | Anti-infective and antithrombogenic medical articles and method for their preparation | |
US4999210A (en) | Anti-infective and antithrombogenic medical articles and method for their preparation | |
US4973320A (en) | Tissue-compatible medical device and method for manufacturing the same | |
JP4786848B2 (en) | Polymer composition containing silver salt colloid | |
Jansen et al. | In-vitro efficacy of a central venous catheter (‘Hydrocath’) loaded with teicoplanin to prevent bacterial colonization | |
US20100068296A1 (en) | Methods for producing an anti-microbial plastic product | |
EP2754413B1 (en) | Medical devices containing nitroprusside and antimicrobial agents | |
US7597903B2 (en) | Method and composition for producing catheters with antibacterial property | |
EP1148898A1 (en) | Lubricious medical devices | |
EP2968686A1 (en) | Polymeric coatings having antimicrobial properties | |
JPH08280790A (en) | Medical material and its production | |
NO972896L (en) | Medical article | |
Szycher | -Antimicrobial Polyurethanes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AZ BY KG KZ RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN |
|
COP | Corrected version of pamphlet |
Free format text: PAGES 1/3-3/3,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;DUE TO LATE TRANSMITTAL BY THERECEIVING OFFICE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1996903614 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2210119 Country of ref document: CA Ref country code: CA Ref document number: 2210119 Kind code of ref document: A Format of ref document f/p: F |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1996 522425 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1996903614 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996903614 Country of ref document: EP |